• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

11.16 +0.42 (+3.91%)
Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 304,952
Open 10.98
Bid (Size) 10.30 (200)
Ask (Size) 11.10 (100)
Prev. Close 10.74
Today's Range 10.98 - 11.24
52wk Range 6.280 - 13.11
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Telix Reports Third Quarter 2026 Financial Performance
Today 18:10 EDT
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
October 19, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire

Performance

52-Week Range 14.9% below 52-week high
11.16
6.2852W Low 13.1152W High
1 Week 0.7% below 1-week high
10.431W Low 11.241W High

Telix Pharmaceuticals Limited - American Depositary Shares (TLX) traded between $6.28 and $13.11 over the past 52 weeks and last traded at $11.16, 14.9% below its 52-week high. Over the past week it ranged between $10.43 and $11.24.

Past 12 Months
+4.8%
-1.3%
+2.2%
+9.1%
+46.5%
+3.4%
1W +$0.51
1M -$0.15
3M +$0.24
6M +$0.93
YTD +$3.54
1Y +$0.37

TLX was +3.4% over the past year, +9.1% over six months, +46.5% year to date, +4.8% in the last week.

12 Months vs Market
TLX
+3.4%
DIA
+12.3%
SPY
+14.6%
QQQ
+17.3%
IWM
+11.1%

Over the past 12 months TLX returned +3.4% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 1.09× 3-mo avg
Today 304,952 3-mo avg 279.7K
1W
261.3K
1M
419.1K
3M
279.7K
6M
224.1K
YTD
232.9K
1Y
212.2K

TLX most recently traded 304,952 shares against a 3-month average daily volume of 279.7K.

More News

Read More
News headline image
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
October 09, 2026
From Profound Medical Corp.
Via GlobeNewswire
News headline image
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
October 06, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
September 20, 2026
From Telix Pharmaceuticals Limited; ITM Isotope Technologies Munich SE
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
September 15, 2026
Via Chartmill
News headline image
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
September 14, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
September 09, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
September 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Appoints David Gill as Chair
August 31, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Pharmaceuticals H1 Earnings Call Highlights ↗
August 19, 2026
Via MarketBeat
Topics Earnings
News headline image
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 19, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Host R&D Day in New York City on September 22, 2026
August 05, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix H1 2026 Results: Investor Webcast Notification
July 30, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
July 21, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
July 20, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
July 20, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
July 15, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
FDA Alignment to Advance ProstACT Global Phase 3 Trial
July 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
June 22, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and United Imaging Announce Strategic Theranostics Collaboration
June 02, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
June 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
May 27, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
May 18, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
May 15, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire

Frequently Asked Questions

Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 11.16
When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 10/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap